MAPT and neurodegenerative disease: In a recent study in the BioFINDER cohort, CSF p‐tau217 measured by an immunoassay distinguished AD dementia from other neurodegenerative diseases better than CSF p‐tau181 and, what is more, correlated better with tau PET and showed higher longitudinal changes than CSF p‐tau181.